Please ensure Javascript is enabled for purposes of website accessibility

Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today

By Dan Caplinger - Dec 24, 2018 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even as the market fell again, these stocks posted gains. Find out why.

The recent drop in the stock market showed no signs of slowing on Monday, as the Dow Jones Industrial Average declined over 600 points. The holiday-shortened trading session didn't curtail investors' nervousness about the financial markets, and an attempt from Treasury Secretary Steve Mnuchin to reassure market participants about the overall health of the financial system only served to raise more concerns about whether things could get worse. Yet some stocks managed to post gains on good underlying news from their companies. Mindbody (MB), New Gold (NGD 6.20%), and Acorda Therapeutics (ACOR -7.13%) were among the best performers on the day. Here's why they did so well.

Mindbody gets a buyout bid

Shares of Mindbody soared 65% after the company got an offer from a private equity investment company to go private. Vista Equity Partners said it would buy the wellness-based software-as-a-service specialist for $36.50 per share in cash, or $1.9 billion overall. Vista co-founder Brian Sheth explained that "Mindbody's position as the leading technology platform for the fitness, beauty and wellness industries makes it an ideal addition to the Vista family of companies." Although Mindbody has a month to find a better offer if it can, the share price move suggests that investors expect the Vista deal to go through.

Orange and gray two-story building near dawn with Mindbody logos and signage.

Image source: Mindbody.

Precious metals help New Gold shine

New Gold's stock was higher by 7% on another solid day for precious metals. Gold bullion prices were higher by $12 per ounce to $1,268, while silver prices climbed about 1% to nearly $14.75 per ounce. That's especially good news for New Gold, which is small enough to be highly levered to gold-price movements. New Gold has seen ups and downs lately, with new leadership working hard to come up with a strategic vision for the gold miner. Yet after the sale of a key asset, some shareholders wonder whether New Gold's most important remaining mine will live up to its promise.

Acorda gets approved

Finally, Acorda Therapeutics saw its shares finish 6% higher. The biotech company announced Monday morning that the U.S. Food and Drug Administration had approved its Inbrija treatment for sufferers of Parkinson's disease. CEO Ron Cohen praised the achievement, noting that "today's approval of Inbrija marks a major milestone for both Acorda and the Parkinson's community, for whom we are gratified to have developed this much-needed therapy." The news eliminated some uncertainty about Acorda's future, and investors hope that the new treatment will overcome the sting of having had patents related to another drug invalidated earlier in the year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acorda Therapeutics, Inc. Stock Quote
Acorda Therapeutics, Inc.
ACOR
$0.52 (-7.13%) $0.04
New Gold Inc. Stock Quote
New Gold Inc.
NGD
$1.20 (6.20%) $0.07
MINDBODY, Inc. Stock Quote
MINDBODY, Inc.
MB

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.